1. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Issue 7 (July 2017) Authors: Harrison, Claire N; Schaap, Nicolaas; Vannucchi, Alessandro M; Kiladjian, Jean-Jacques; Tiu, Ramon V; Zachee, Pierre; Jourdan, Eric; Winton, Elliott; Silver, Richard T; Schouten, Harry C; Passamonti, Francesco; Zweegman, Sonja; Talpaz, Moshe; Lager, Joanne; Shun, Zhenming; Mesa, Ruben A Journal: Lancet Issue: Volume 4:Issue 7(2017) Page Start: e317 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147), a Pan-Class I PI3K Inhibitor, in Combination With Erlotinib in Patients With Solid Tumors. (10th February 2015) Authors: Soria, Jean-Charles; LoRusso, Patricia; Bahleda, Ratislav; Lager, Joanne; Liu, Li; Jiang, Jason; Martini, Jean-François; Macé, Sandrine; Burris, Howard Journal: Oncologist Issue: Volume 20:Number 3(2015) Page Start: 245 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Phase I Dose‐Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors. (8th March 2017) Authors: Wheler, Jennifer; Mutch, David; Lager, Joanne; Castell, Christelle; Liu, Li; Jiang, Jason; Traynor, Anne M. Journal: Oncologist Issue: Volume 22:Number 4(2017) Page Start: 377 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Phase I Dose‐Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors. (April 2017) Authors: Wheler, Jennifer; Mutch, David; Lager, Joanne; Castell, Christelle; Liu, Li; Jiang, Jason; Traynor, Anne M. Journal: Oncologist Issue: Volume 22:Number 4(2017) Page Start: 377 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Phase I Dose‐Escalation Study of Pilaralisib (SAR245408, XL147), a Pan‐Class I PI3K Inhibitor, in Combination With Erlotinib in Patients With Solid Tumors. (10th February 2015) Authors: Soria, Jean‐Charles; LoRusso, Patricia; Bahleda, Ratislav; Lager, Joanne; Liu, Li; Jiang, Jason; Martini, Jean‐François; Macé, Sandrine; Burris, Howard Journal: Oncologist Issue: Volume 20:Number 3(2015) Page Start: 245 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan‐Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors. (30th March 2018) Authors: Edelman, Gerald; Rodon, Jordi; Lager, Joanne; Castell, Christelle; Jiang, Jason; Van Allen, Eliezer M.; Wagle, Nikhil; Lindeman, Neal I.; Sholl, Lynette M.; Shapiro, Geoffrey I. Journal: Oncologist Issue: Volume 23:Number 4(2018) Page Start: 401 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B‐cell malignancies. (13th June 2016) Authors: Awan, Farrukh T.; Gore, Lia; Gao, Lei; Sharma, Jyoti; Lager, Joanne; Costa, Luciano J. Journal: British journal of haematology Issue: Volume 175:Number 1(2016) Page Start: 55 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗